CHAIN ANTIMICROBIALS Ltd

Who we are

Chain Antimicrobials Ltd has developed an effective solution to restrict the spread of Catheter-Associated Urinary Tract Infections (CAUTI). The company’s product, peptide-coated catheters (PAC) will improve the quality of life of patients by reducing the severity of urinary tract infections. Consequently, the length of patients stay in a hospital will shorten noticeably.

Our solution

CHAIN Antimicrobials Ltds lead product, peptide-coated catheters (PAC) have shown positive results in in-vitro studies. The tests show a high promise of success in preventing the spread of Hospital-acquired infections (HAIs), especially the Catheter-Associated Urinary Tract Infections. The preclinical and clinical studies are in progress to test the efficacy of the product in animals and human patients. The widespread usage of PAC may even curb these infections completely. This product will improve the quality of life of patients, reduce the severity of UTIs and the financial burden on patients or healthcare provider, resulting in no extra days spent in the hospital. In short, the lives of the patients is significantly improved with the use of our product.

Benefits

The widespread usage of Peptide-Coated-Catheters (PAC) may even curb these infections completely. This product will improve the quality of life of patients, reduce the severity of UTIs and the financial burden on patients or healthcare provider, resulting in no extra days spent in the hospital. In short, the lives of the patients is significantly improved with the use of our product. The product has high efficacy and safety as tested by the ISO 10993-5 (2009), & ISO 10993-12 (2012) and the peptides are passively coated on catheters meaning it does not release and it is easy to manufacture. The PAC by CHAIN ANTIMICROBIALS Ltd could thus eliminate catheter-associated urinary tract infections on a global level.

What are we looking for

We are looking for partners for collaboration and joint ventures for application of our technology in a various healthcare setting. If your company is interested in having a dialogue with us, then please do contact us.

Team profiles

Tejesvi Mysore

Adjunct Professor Tejesvi Mysore has over 15 years of experience working both in academia and industry on antimicrobials (2 years at Novozymes, Denmark) and was involved in several projects to find bioactive compounds and peptides from endophytes of medicinal plants. He was the Principal Investigator (PI) of Tekes - TUTLI project aiming to develop antimicrobial peptides for commercial applications in healthcare. He was awarded Marie Curie fellowship in 2008 to carry out his postdoctoral work. He has 39 peer-reviewed publications, 4 patent applications on the subject of bioactive peptides/compounds, and two invention disclosures.

Anna Maria Pirttilä

Adjunct and Associate Professor AM Pirttilä has over 20 years of experience in the research of plant-associated microbes and their bioactive compounds. She has worked for two years at Purdue University, Indiana, USA and hosted the Research Fellow position of the Academy of Finland, as well as lead two EU - funded (FP7) and one TEKES - funded projects. In 2016, she was the candidate for Scientist of the Year in Finland. Currently, she has a list of 130 publications (>60 peer-reviewed), 7 invention disclosures/patent applications and 4 book editions.

Juhani Lahdenperä

Juhani has more 10 years of business experience in the field of life sciences in Finland. He has been working for the past 7 years as a CEO in two start-up companies (PlexPress and Hermo Pharma). He has secured / executed 3 exits / exit positions previously. He has raised more than 9 million EUR funding for the companies and academic commercialisation projects which he has represented in the past.

Tomi Järvinen

MBA, ECCP, has 15 years’ experience from clinical medical work, mostly in critical health care field such as cardiac surgery. Post clinical work, he has been working for the past 12 years in different positions of medical companies, focusing on the sales and market development and launching new products in the market. He has been working as a Business Leader in Nordic countries for the past 6 years.

Contact information

Tejesvi Mysore, Ph.D., Doc.

Chief Executive Officer

tejesvi.mysore@chainantimicrobials.com

+358406303377 (office)

chainantimicrobials.com/

Related posts